| Gail Elizabeth Tomlinson, MD | |
|
333 N Santa Rosa, Eighth Floor, San Antonio, TX 78207-3108 | |
| (210) 257-1400 | |
| (210) 257-1428 |
| Full Name | Gail Elizabeth Tomlinson |
|---|---|
| Gender | Female |
| Speciality | Pediatrics - Pediatric Hematology-oncology |
| Location | 333 N Santa Rosa, San Antonio, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316905268 | NPI | - | NPPES |
| 102174306 | Other | TX | CSHCN |
| 102174305 | Medicaid | TX |
| Entity Name | Community Medicine Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245313329 PECOS PAC ID: 7719979509 Enrollment ID: O20040401000372 |
News Archive
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
House Research Institute (HRI) and Children's Hospital Los Angeles Children's Hospital) announced today final approval of grant funding by the National Institutes of Health (NIH) National Institute on Deafness and Communications Disorders (NIDCD) for a major five-year, FDA-approved clinical trial of the auditory brainstem implant (ABI) in children.
A new study describes a therapeutic approach to halting cancer progression by exploiting a previously unrecognized "addiction" of leukemia cells to specific signaling molecules. The research, published by Cell Press online on April 16th in the journal Cancer Cell, identifies non-classical oncogenes critical for tumor development and survival, and describes a potentially less toxic strategy that selectively targets these molecules.
The National Institute for Occupational Safety and Health has awarded U of U Health funding to establish a new Utah-based Center of Excellence for Total Worker Health as part of its national initiative to improve workplace wellness and safety through innovative collaborative work.
Administering high-doses of interleukin-2 (IL-2) has been the preferred treatment for patients with stage IV metastatic melanoma. An article published in the current issue of Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., explores whether or not this regimen is still the most effective.
› Verified 3 days ago
| Entity Name | University Of Texas Health Science Center At San Antonio |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720051717 PECOS PAC ID: 0042128548 Enrollment ID: O20040607000664 |
News Archive
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
House Research Institute (HRI) and Children's Hospital Los Angeles Children's Hospital) announced today final approval of grant funding by the National Institutes of Health (NIH) National Institute on Deafness and Communications Disorders (NIDCD) for a major five-year, FDA-approved clinical trial of the auditory brainstem implant (ABI) in children.
A new study describes a therapeutic approach to halting cancer progression by exploiting a previously unrecognized "addiction" of leukemia cells to specific signaling molecules. The research, published by Cell Press online on April 16th in the journal Cancer Cell, identifies non-classical oncogenes critical for tumor development and survival, and describes a potentially less toxic strategy that selectively targets these molecules.
The National Institute for Occupational Safety and Health has awarded U of U Health funding to establish a new Utah-based Center of Excellence for Total Worker Health as part of its national initiative to improve workplace wellness and safety through innovative collaborative work.
Administering high-doses of interleukin-2 (IL-2) has been the preferred treatment for patients with stage IV metastatic melanoma. An article published in the current issue of Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., explores whether or not this regimen is still the most effective.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gail Elizabeth Tomlinson, MD 7703 Floyd Curl Dr, Mc 7977, San Antonio, TX 78229-3901 Ph: (210) 257-1400 | Gail Elizabeth Tomlinson, MD 333 N Santa Rosa, Eighth Floor, San Antonio, TX 78207-3108 Ph: (210) 257-1400 |
News Archive
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
House Research Institute (HRI) and Children's Hospital Los Angeles Children's Hospital) announced today final approval of grant funding by the National Institutes of Health (NIH) National Institute on Deafness and Communications Disorders (NIDCD) for a major five-year, FDA-approved clinical trial of the auditory brainstem implant (ABI) in children.
A new study describes a therapeutic approach to halting cancer progression by exploiting a previously unrecognized "addiction" of leukemia cells to specific signaling molecules. The research, published by Cell Press online on April 16th in the journal Cancer Cell, identifies non-classical oncogenes critical for tumor development and survival, and describes a potentially less toxic strategy that selectively targets these molecules.
The National Institute for Occupational Safety and Health has awarded U of U Health funding to establish a new Utah-based Center of Excellence for Total Worker Health as part of its national initiative to improve workplace wellness and safety through innovative collaborative work.
Administering high-doses of interleukin-2 (IL-2) has been the preferred treatment for patients with stage IV metastatic melanoma. An article published in the current issue of Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., explores whether or not this regimen is still the most effective.
› Verified 3 days ago
Dr. Wilson Wayne Grant, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 5282 Medical Dr, Ste 310, San Antonio, TX 78229 Phone: 210-614-8687 Fax: 210-614-7529 | |
Dr. Jane T Atkins, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 7922 Ewing Halsell Dr, Suite 270, San Antonio, TX 78229 Phone: 210-614-2828 Fax: 210-614-2558 | |
Pedro Nelson Chavez, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 520 Madison Oak Dr, Suite 103, San Antonio, TX 78258 Phone: 210-297-8640 Fax: 210-297-8640 | |
Dr. Jose F Pascual-baralt, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 7419 Round Mtn, San Antonio, TX 78255 Phone: 210-695-2906 | |
Mr. Byron Scott Dooley, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 525 Oak Centre, Suite 350, San Antonio, TX 78258 Phone: 210-297-4560 Fax: 210-297-0451 | |
Dr. Elizabeth Christiane Diltz Menking, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 7700 Floyd Curl, San Antonio, TX 78229 Phone: 210-871-4409 Fax: 210-524-9599 | |
Dr. Lauren Elizabeth Munk, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 19223 Stonehue Ste 117, San Antonio, TX 78258 Phone: 210-491-0772 Fax: 210-491-2769 |